Physician profile
Gregory Singleton
NPI 1417114018
$1,301.03
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $179 · 2021: $430 · 2022: $249 · 2023: $16.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $241.44 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $240.96 | 2019-2021 | |
| Abbvie INC. | $152.53 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $129.99 | 2020 | |
| Neurocrine Biosciences, INC. | $111.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.24 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $68.59 | 2019-2021 | |
| Adlon Therapeutics L.P. | $58.07 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $47.17 | 2021-2022 | |
| Lundbeck LLC | $27.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.51 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.22 | 2021 | |
| Neos Therapeutics, Lp | $19.88 | 2020 | |
| Vertical Pharmaceuticals, LLC | $19.32 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.76 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $16.06 | 2023 | Xelstrym |
| Tris Pharma INC | $12.00 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.84 | 2019 | |
| Bausch Health US, LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.